Tag : TwoYear

Cardiology

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Newsemia
Related Articles Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019 11;19(11):3018-3034...
Cardiology

Two-Year Outcomes After Deferral of Revascularization Based on Fractional Flow Reserve: The J-CONFIRM Registry.

Newsemia
Related Articles Two-Year Outcomes After Deferral of Revascularization Based on Fractional Flow Reserve: The J-CONFIRM Registry. Circ Cardiovasc Interv. 2020 01;13(1):e008355 Authors: Kuramitsu S, Matsuo...
Surgery/Cosmetic

Objective assessment of surgical trainees’ non-technical skills: Improved performance following a two-year program of instruction

Newsemia
Non-technical skills (NTS) encompass personal skills such as communication, situational awareness, decision making, teamwork and leadership. Poor performance of these skills has been shown to...
Latest News

Prestigious two-year fellowship awarded to Ofelia Martinez from Hackensack Meridian Health

Newsemia
Ofelia Martinez, the director of clinical skills at the Hackensack Meridian School of Medicine at Seton Hall University, was awarded a prestigious two-year fellowship by...
Latest News

Scientist wins two-year grant for diagnosis of Alzheimer's, Parkinson's via innovative skin test

Newsemia
Wenquan Zou, MD, PhD, an expert in prion and degenerative neurological diseases, has received a two-year grant for developing diagnostic tools for Alzheimer’s disease, Parkinson’s...
AI/ML

A Look Inside GM’s Two-Year, Entry-Level Rotational Program

Newsemia
Fortune’s Entry/Level column is dedicated to people looking for and working in entry-level positions–read the full series here. We interview entry-levelers about their jobs, how...
Latest News

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

Newsemia
SAN DIEGO–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in patients with refractory...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World